


I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Mail Bill No. ER147061760, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: June 17, 2003

Signature: *Susan Hunter*
(Susan Hunter)



#9158
6/23/03
Docket No.: HO-P02086US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
James R. Lupski, et al

Application No.: 10/021,955

Group Art Unit: 1637

Filed: December 13, 2001

Examiner: S. Chunduru

(10026309)

For: DEFECTS IN PERIAXIN ASSOCIATED WITH
MYELINOPATHIES

RECEIVED
JUN 20 2003
TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT AND PRELIMINARY AMENDMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This is in response to the restriction requirement set forth in the Office Action mailed February 19, 2003. A Petition for Extension of Time of Three Months and the requisite fee are filed herewith.

The Examiner has required restriction between the following:

Group I (Claims 1-13), drawn to a method of diagnosing myelinopathy in an individual based on an alteration in a periaxin polynucleotide, requiring SEQ ID NOS:1-77;

Group II (Claims 14, 32-34), drawn to a composition of matter and a kit comprising a polynucleotide, requiring SEQ ID NOS:3-26;

Group III (Claims 15-16), drawn to a composition of matter comprising a polypeptide;

Group IV (Claims 17-20), drawn to a method of identifying or screening a compound agent for treating a myelinopathy;

Group V (Claims 21-23), drawn to a method of identifying an upregulator or a drug activity;

Group VI (Claims 24-26), drawn to a method of treating an organism comprising a therapeutically effective amount of a nucleic acid sequence;

Group VII (Claims 27-28), drawn to a method of treating an organism comprising a therapeutically effective amount of an amino acid sequence;

Group VIII (Claims 29-31), drawn to a method of treating an organism comprising a therapeutically effective amount of a compound; and

Group IX (Claims 35-40), drawn to a method of detecting the presence or absence of a mutation associated with a myelinopathy, requiring SEQ ID NOS:1-77.

Applicants, represented by Melissa L. Sistrunk, telephoned Examiner Chunduru on March 27, 2003 regarding grouping of the claims. Applicants notified the Examiner that Group I drawn to Claims 1-13 erroneously grouped claims directed to polypeptide sequences, and suggested Group I should include only Claims 1-7. The Examiner agreed.

Applicants also discussed with the Examiner the nature of restriction between Group I and Group IX, and the Examiner suggested addressing the issue in the response.

Applicants traverse the restriction between Group I and Group IX. The claims in Group I are directed to a method of diagnosing myelinopathy in an individual by obtaining a sample containing nucleic acid from the individual; and assaying the sample for an alteration in a periaxin polynucleotide, wherein the alteration is associated with the myelinopathy. Group IX is directed to a method of detecting the presence or absence of a mutation associated with a myelinopathy by isolating a test periaxin nucleic acid from a subject, comparing the test nucleic acid to a reference wild-type periaxin polynucleotide; and determining the differences between the test nucleic acid and the reference wild-type periaxin polynucleotide, wherein the differences are mutations in the periaxin polynucleotide of the subject, and wherein the presence of a mutation in the periaxin polynucleotide of the subject is associated with the myelinopathy in the subject.

Applicants respectfully assert that the two groups regard the same invention, with substantially similar steps. Both independent claims, and therefore corresponding Groups, regard obtaining a periaxin polynucleotide and determining whether or not a mutation is present in the periaxin polynucleotide, wherein a mutation in the periaxin polynucleotide is associated with a myelinopathy. Applicants suggest that there would be no undue burden to employ searches for both Groups, as both Groups are so similar in nature. Therefore, Applicants respectfully request consolidation of Group I (the correct one, with only the polynucleotide sequences) and Group IX.

If the Examiner agrees, then Applicants select new Group I/Group IX and elect as a species 247ΔC. If the Examiner does not agree, then Applicants select Group IX and elect as a species 247ΔC. Upon the request of the Examiner, Applicants also select the species SEQ ID NO:76 as the specific nucleotide sequence for examination purposes only.

Applicant reserves the right to pursue non-elected claims in future prosecution and will cancel any remaining non-elected claims upon resolving this grouping issue.

06-18-03

16374



PTO/SB/21 (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)


TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>		Application Number	10/021,955
		Filing Date	December 13, 2001
		First Named Inventor	James R. Lupski
		Art Unit	1637
Examiner Name	S. Chunduru		
Total Number of Pages in This Submission		Attorney Docket Number	HO-P02086US1

RECEIVED
TECH CENTER 1600/2000
JUN 20 2003

ENCLOSURES (check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input checked="" type="checkbox"/> Fee Attached - \$465 <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input checked="" type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Response to Restriction Requirement; Return Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	FULBRIGHT & JAWORSKI L.L.P. Melissa L. Sistrunk
Signature	
Date	June 17, 2003

Transmittal

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ER14706170US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: June 17, 2003

Signature:  (Susan Hunter)